Sun Chemical Corporation v. Fike Corporation (082815)(Statewide) ( 2020 )


Menu:
  •                                        SYLLABUS
    This syllabus is not part of the Court’s opinion. It has been prepared by the Office of the
    Clerk for the convenience of the reader. It has been neither reviewed nor approved by the
    Court. In the interest of brevity, portions of an opinion may not have been summarized.
    Sun Chemical Corporation v. Fike Corporation (A-89-18) (082815)
    Argued March 17, 2020 -- Decided July 29, 2020
    SOLOMON, J., writing for the Court.
    In this case the Court considers, in response to a question of law certified to
    the Court by the United States Court of Appeals for the Third Circuit pursuant to
    Rule 2:12A-3, whether a Consumer Fraud Act (CFA) claim can be based, in part or
    exclusively, on a claim that also might be actionable under the Products Liability
    Act (PLA).
    Sun Chemical Corporation (Sun) purchased an explosion isolation and
    suppression system (Suppression System) from Fike Corporation and Suppression
    Systems Incorporated (collectively, Fike) to prevent and contain potential explosions
    in its new dust collection system. On the first day that the Suppression System was
    operational, a fire occurred, and an alarm on the Suppression System’s control panel
    activated but was not audible. An explosion sent a fireball through the ducts of the
    dust collection system, injuring seven Sun employees and damaging Sun’s facility.
    Sun brought a single-count complaint under the CFA in federal court alleging
    that Fike made oral and written misrepresentations about four aspects of the
    Suppression System: (1) the Suppression System would prevent explosions; (2) the
    Suppression System would have an audible alarm; (3) the Suppression System
    complied with industry standards; and (4) the system had never failed. The District
    Court granted Fike’s summary judgment motion, finding that Sun’s claims would be
    governed by the PLA and that it could not avoid the requirements of the PLA by
    crafting its claims under the CFA. Sun appealed, and after determining that extant
    New Jersey case law was not sufficiently on point to guide its determination of
    which of the two statutes to apply, the Third Circuit certified its questions to the
    Court, which the Court reformulated and accepted.         N.J.       (2019).
    HELD: The Court answers the certified question in the affirmative. A CFA claim
    alleging express misrepresentations -- deceptive, fraudulent, misleading, and other
    unconscionable commercial practices -- may be brought in the same action as a PLA
    claim premised upon product manufacturing, warning, or design defects. It is the
    nature of the claims brought, not the nature of the damages sought, that is
    dispositive of whether the PLA precludes the separate causes of action. In other
    1
    words, the PLA will not bar a CFA claim alleging express or affirmative
    misrepresentations.
    1. There is no authority directly addressing the interplay between the CFA and PLA
    in this setting, but their statutory language, legislative history, and the Court’s
    relevant jurisprudence regarding both statutes inform the Court’s answer to the
    question before it. The CFA prohibits deceptive, fraudulent, misleading, and other
    unconscionable commercial practices in connection with the sale of any merchandise
    or real estate. The language of the CFA evinces a clear legislative intent that its
    provisions be applied broadly. In Lemelledo v. Beneficial Management Corp. of
    America, 
    150 N.J. 255
    , 259-60, 271-73 (1997), a consumer brought a class action
    under the CFA against a financial services company for loan packing and the
    defendant argued that the CFA was preempted by other statutes regulating consumer
    loans. The Court rejected that argument, holding there is a “presumption that the
    CFA applies to a covered activity,” and the presumption can be overcome only when
    a court is satisfied “that a direct and unavoidable conflict exists between application
    of the CFA and application of the other regulatory scheme or schemes.”
    Id. at 270.
    In Real v. Radir Wheels, Inc., 
    198 N.J. 511
    , 514, 526 (2009), the Court applied the
    principles set forth in Lemelledo and held that the Used Car Lemon Law did not
    preempt a CFA claim for fraudulent advertisement brought by the purchaser of a
    used automobile from a private seller. (pp. 8-13)
    2. The PLA imposes liability upon the manufacturer or seller for a product’s
    manufacturing, warning, and design defects. Under the PLA, a claimant can recover
    damages against the manufacturer or seller of a product upon proof that the product
    causing the harm was not reasonably fit, suitable or safe for its intended purpose. In
    In re Lead Paint Litigation, 
    191 N.J. 405
    , 436-37 (2007), the Court scrutinized a
    nuisance-based pleading and, based on a pleading-to-statute comparison, held that
    the PLA subsumed the plaintiffs’ common law public nuisance causes of action that
    were fundamentally PLA claims. The Court determined that the theory of liability
    claimed by the plaintiffs was, in reality, a PLA claim and was therefore actionable
    only under the strictures of the PLA.
    Id. at 440.
    In Sinclair v. Merck & Co., 
    195 N.J. 51
    , 54 (2008), the Court considered whether plaintiffs who used the drug Vioxx
    could maintain both CFA and PLA claims. The Court determined, after considering
    the nature of the plaintiffs’ allegations, that the plaintiffs sought “to avoid the
    requirements of the PLA by asserting their claims as CFA claims,” even though
    “[t]he heart of [their] case [was] the potential for harm caused by Merck’s drug.”
    Id. at 65-66.
    (pp. 13-18)
    3. The CFA and PLA are intended to govern different conduct and to provide
    different remedies for such conduct. There is thus no direct and unavoidable
    conflict between the CFA and PLA. The PLA governs the legal universe of products
    liability actions as defined in that Act and the CFA applies to fraud and
    2
    misrepresentation and provides unique remedies intended to root out such conduct.
    Although the Court has rejected the idea that contract-based claims could be pled
    under the PLA, the Court has not yet considered the question at the center of this
    matter: whether tort-based claims that can be pled under the PLA can also -- or
    instead -- be pled under the CFA. The failure to warn of a product defect is
    cognizable under the PLA, while an affirmative misrepresentation that a specific
    flaw did not exist, or a product had never failed may be brought under the CFA. If a
    claim is premised upon a product’s manufacturing, warning, or design defect, that
    claim must be brought under the PLA with damages limited to those available under
    that statute; CFA claims for the same conduct are precluded. But nothing about the
    PLA prohibits a claimant from seeking relief under the CFA for deceptive,
    fraudulent, misleading, and other unconscionable commercial practices in the sale of
    the product. Indeed, the CFA is expressly “in addition to and cumulative of any
    other right, remedy or prohibition accorded by the common law or statutes of this
    State.” N.J.S.A. 56:8-2.13. (pp. 18-20)
    4. Said differently, if a claim is based on deceptive, fraudulent, misleading, and
    other unconscionable commercial practices, it is not covered by the PLA and may be
    brought as a separate CFA claim. PLA and CFA claims may proceed in separate
    counts of the same suit, alleging different theories of liability and seeking dissimilar
    damages. Had the Legislature intended for the PLA to preempt, displace, or
    subsume the CFA, it would have said so. Neither the Federal Rules of Civil
    Procedure nor the New Jersey Court Rules preclude separate claims premised upon
    separate theories of liability from being advanced in the same pleading and sought at
    the same trial. (pp. 20-21)
    5. How a given claim must be pled depends on the underlying theory of liability.
    The phrase “the essential nature of the claim[]” in Lead Paint is best understood not
    as an assessment of whether a claim is for harm caused by a product, but of whether
    the claim is based upon a product’s manufacturing, warning, or design defect and
    therefore covered by the PLA. Significantly, it is the nature of the action giving rise
    to a claim that determines how a claim is characterized. Sun is mistaken in its heavy
    reliance on the nature of the damages it seeks. The nature of the plaintiff’s damages
    does not determine whether the cause of action falls under the CFA or PLA; rather,
    it is the theory of liability underlying the claim that determines the recoverable
    damages. (pp. 21-24)
    CHIEF JUSTICE RABNER and JUSTICES LaVECCHIA, ALBIN, and
    FERNANDEZ-VINA join in JUSTICE SOLOMON’s opinion. JUSTICES
    PATTERSON and TIMPONE did not participate.
    3
    SUPREME COURT OF NEW JERSEY
    A-89 September Term 2018
    082815
    Sun Chemical Corporation,
    Plaintiff-Appellant,
    v.
    Fike Corporation and Suppression
    Systems Incorporated,
    Defendants-Respondents.
    On certification of question of law from the United
    States Court of Appeals for the Third Circuit.
    Argued                        Decided
    March 17, 2020                July 29, 2020
    Lance J. Kalik argued the cause on behalf of appellant
    (Riker Danzig Scherer Hyland & Perretti, attorneys;
    Lance J. Kalik, of counsel and on the briefs, and
    Jeffrey A. Beer, Jr., on the briefs).
    Gino P. Mecoli argued the cause on behalf of
    respondents (Reilly, McDevitt & Henrich, attorneys;
    Gino P. Mecoli and Suzanne I. Turpin, on the brief).
    Christopher M. Placitella argued the cause on behalf
    of amicus curiae New Jersey Association of Justice
    (Cohen, Placitella & Roth, attorneys; Christopher M.
    Placitella, Jared M. Placitella, and Michael Coren, of
    counsel and on the brief).
    1
    Kevin R. Jespersen, Assistant Attorney General,
    argued the cause on behalf of amicus curiae Attorney
    General of New Jersey (Gurbir S. Grewal, Attorney
    General, attorney; Jason W. Rockwell, Assistant
    Attorney General and Janine N. Matton, Assistant
    Attorney General, of counsel, and Zachary N. Klein,
    Deputy Attorney General, on the brief).
    JUSTICE SOLOMON delivered the opinion of the Court.
    New Jersey’s Consumer Fraud Act (CFA), N.J.S.A. 56:8-1 to -224, and
    Products Liability Act (PLA), N.J.S.A. 2A:58C-1 to -11, are remedial statutes
    that target different wrongs, address distinct types of harm, and provide for
    divergent remedies.
    The CFA is to be expansively read to proscribe unconscionable business
    practices. The PLA’s reach is more limited -- it permits pursuit of product
    liability claims brought by “claimants” for “harm,” as those terms are defined
    in the statute. Just as the PLA is more limited in scope, it is more limited in
    remedy: it provides only for damages traditionally available in tort actions,
    such as remuneration for destroyed property, emotional distress, and loss of
    consortium; the CFA on the other hand entitles successful plaintiffs to treble
    damages, costs, and attorney’s fees.
    In this case we consider, in response to a question of law certified by the
    United States Court of Appeals for the Third Circuit pursuant to Rule 2:12A-3,
    2
    whether “a Consumer Fraud Act claim [can] be based, in part or exclusively,
    on a claim that also might be actionable under the Products Liability Act .”1
    1
    In accepting the certified question, ___ N.J. ___ (2019), we exercised our
    authority under Rule 2:12A-2 to reformulate as the single question indicated
    above the following questions posed by the Third Circuit:
    (1) When a court decides a CFA claim based on
    affirmative and material misrepresentation about the
    features of a product, but the plaintiff is seeking
    damages for harm caused by the product’s failure to
    conform to those features, what criteria should the court
    consider to determine whether the claim may proceed
    as a CFA claim or is subsumed under the PLA?
    (2) In determining whether a claim may proceed under
    the CFA or is subsumed under the PLA, what
    significance should a court place on a plaintiff’s
    assertion that its harm resulted primarily from physical
    injury to third parties (like employees) rather than
    property damage or personal physical injury?
    (3) Where a complaint pleads a single CFA claim that
    asserts multiple harms, some of which fall within the
    ambit of the PLA, and others which do not, is the entire
    claim subsumed by the PLA or should the distinct
    categories of harm be deemed severable claims, some
    of which would not be subsumed and could instead be
    pursued under the CFA?
    (4) Under the CFA, when can a commercial purchaser
    of a product recover consequential economic losses --
    such as workers’ compensation payments, attorneys’
    fees incurred in litigation, fees incurred in government
    investigations, and increased labor or production costs
    -- based on alleged misrepresentations the seller made
    about the features and capabilities of the product?
    3
    We conclude that, irrespective of the nature of the damages, a CFA
    claim alleging express misrepresentations -- deceptive, fraudulent, misleading,
    and other unconscionable commercial practices -- may be brought in the same
    action as a PLA claim premised upon product manufacturing, warning, or
    design defects. It is the nature of the claims brought, and not the nature of the
    damages sought, that is dispositive of whether the PLA precludes the separate
    causes of action. In other words, the PLA will not bar a CFA claim alleging
    express or affirmative misrepresentations.
    I.
    A.
    We rely upon the following facts provided by the opinions of the Third
    Circuit and the United States District Court for the District of New Jersey.
    Sun Chemical Corporation (Sun) has long operated an ink manufacturing
    business in New Jersey. In 2012, Sun installed a new dust collection system at
    its facility. Sun then purchased an explosion isolation and suppression system
    (Suppression System) from Fike Corporation and Suppression Systems
    Incorporated (collectively, Fike) to prevent and contain potential explosions in
    that dust collection system.
    On the first day that the Suppression System was operational, a fire
    occurred in the dust collection system and an alarm on the Suppression
    4
    System’s control panel activated but was not audible. Sun employees
    attempted to extinguish the fire, but an explosion sent a fireball through the
    ducts of the dust collection system, injuring seven Sun employees and causing
    damage to Sun’s facility.
    B.
    Sun brought a single-count complaint under the CFA alleging that Fike
    made material oral and written misrepresentations about four aspects of the
    Suppression System: (1) the Suppression System would prevent explosions;
    (2) the Suppression System would have an audible alarm; (3) the Suppression
    System complied with industry standards; and (4) the system had never failed.
    Following discovery, both parties moved for summary judgment. The District
    Court granted Fike’s motion, finding that Sun’s claims would be governed by
    the PLA and noting that “a plaintiff may not avoid the requirements of the
    PLA by artfully crafting its claims under the CFA.”
    Sun appealed, and the Third Circuit noted that, although “the
    resemblance of Sun’s claim to a product liability action” suggests it would fall
    under the PLA, the plain text of the CFA seems potentially hospitable to Sun’s
    argument that “affirmative misrepresentations can be brought under the CFA
    . . . even though the damages claimed for those representations involve[]
    personal injuries to third parties and some property damage.” After
    5
    determining that extant New Jersey case law was not sufficiently on point to
    guide its determination of which of the two statutes to apply, the Third Circuit
    certified its questions to this Court.
    After reformulating and accepting the question, we granted motions by
    the New Jersey Attorney General and the New Jersey Association for Justice
    (NJAJ) to participate as amici curiae. We consider their arguments along with
    those of the parties.
    II.
    Sun concedes that five percent of its losses result from damage to its
    facility and are “physical damage to property” -- a “harm” specifically
    identified in N.J.S.A. 2A:58C-1(b)(2)(a), a section of the PLA. Sun maintains
    that the PLA is nevertheless inapplicable to those losses because they resulted
    from Fike’s misrepresentations, not alleged defects.
    Sun argues that the cost of the failed Suppression System likewise does
    not fall within the PLA, which explicitly excludes from its definition of
    “harm” in N.J.S.A. 2A:58C-1(b)(2)(a) any “damage . . . to the product itself.”
    According to Sun, the cost of the Suppression System is a purely economic
    loss outside the scope of the PLA but specifically cognizable under the CFA.
    Sun further contends that lost workhours and workers’ compensation
    benefits paid as a result of injuries to its employees are purely economic losses
    6
    and thus do not establish “loss deriving from” personal injury within the
    meaning of N.J.S.A. 2A:58C-1(b)(2)(b) or (b)(2)(d) of the PLA. In support,
    Sun notes that the PLA codified the economic loss doctrine, 2 which provides
    that economic loss resulting from harm to employees is not a cognizable “loss
    deriving from” personal injury. In any case, Sun suggests that it should be
    able to proceed with a PLA count for its PLA damages and a separate count for
    its non-PLA damages.
    Fike argues that the cost of the Suppression System does not qualify as
    “damage . . . to the product itself” under N.J.S.A. 2A:58C-1(b)(2)(a) because
    the Suppression System was not defective and was not damaged during the
    explosion. Fike further contends that the losses resulting from injuries to
    Sun’s employees constitute “loss deriving from” personal injury under
    N.J.S.A. 2A:58C-1(b)(2)(b) and (b)(2)(d). Fike asserts that Sun cannot avoid
    application of the PLA by pleading only economic damages. Rather, Fike
    argues, New Jersey courts look to the “essential nature of the claim” and will
    apply the PLA where appropriate, regardless of how the claim is pled.
    2
    The economic loss doctrine prohibits the recovery in a tort action of
    economic losses arising out of a breach of contract. See Dean v. Barrett
    Homes, Inc., 
    204 N.J. 286
    , 296-97 (2010). Thus, under the economic loss
    doctrine, “the [PLA] and common law tort actions do not apply to damage
    caused to the product itself, or to consequential but purely economic losses
    caused to the consumer because of a defective product.” Ford Motor Credit
    Co., LLC v. Mendola, 
    427 N.J. Super. 226
    , 240 (App. Div. 2012).
    7
    Amicus curiae NJAJ argues that CFA and PLA claims should be able to
    proceed concurrently if both are supported by the facts. NJAJ asserts that the
    correct reading of the two statutes is that, “[s]ince representation-based claims
    and products liability claims deal with two distinct categories of unlawful
    conduct rather than two different theories covering the same underlying
    conduct, the PLA does not subsume representation-based claims.” (quoting
    Francis E. Parker Mem’l Home, Inc. v. Georgia-Pacific LLC, 
    945 F. Supp. 2d 543
    , 556 n.5 (D.N.J. 2013)).
    The Attorney General argues that recovery under the PLA is limited to
    those tort-based theories of recovery for losses that fit the PLA definition of
    harm. The Attorney General also asserts that losses premised on non-tort
    theories of recovery and losses that do not fit the PLA definition of harm can
    proceed in separate counts of the same suit as PLA counts.
    III.
    There is no authority directly addressing the interplay between the CFA
    and PLA in this setting. Nevertheless, their statutory language, legislative
    history, and this Court’s relevant jurisprudence regarding both statutes inform
    our answer to the question before us. We therefore begin by reviewing the
    pertinent provisions of the CFA and PLA, their purposes, and cases applying
    them.
    8
    A.
    The Legislature passed the CFA in 1960 “to permit the Attorney General
    to combat the increasingly widespread practice of defrauding the consumer.”
    Cox v. Sears Roebuck & Co., 
    138 N.J. 2
    , 14 (1994) (quoting S. Comm.
    Statement to S. 199 (1960)). In so doing, the Legislature “intended to confer
    on the Attorney General the broadest kind of power to act in the interest of the
    consumer public.” Kugler v. Romain, 
    58 N.J. 522
    , 537 (1971).
    The CFA prohibits deceptive, fraudulent, misleading, and other
    unconscionable commercial practices “in connection with the sale . . . of any
    merchandise or real estate.” N.J.S.A. 56:8-2. “Merchandise” is broadly
    defined to “include any objects, wares, goods, commodities, services or
    anything offered, directly or indirectly to the public for sale.” N.J.S.A. 56:8-
    1(c). For the purposes of this certified question, the parties do not dispute that
    the Suppression System is a product offered to the public for sale.
    In 1971, the Legislature amended the CFA to provide for private causes
    of action by consumers to recover for an “ascertainable loss of moneys or
    property, real or personal.” Weinberg v. Sprint Corp., 
    173 N.J. 233
    , 247-51
    (2002) (quoting N.J.S.A. 56:8-19). The amendment also enabled successful
    private plaintiffs to recover treble damages, reasonable attorneys’ fees and
    costs, and “any other appropriate legal or equitable relief.”
    Id. at 250
    (quoting
    9
    N.J.S.A. 56:8-19). The private right of action “is integral to fulfilling the
    [CFA’s] legislative purposes,” 
    Cox, 138 N.J. at 16
    , and by allowing recovery
    of attorneys’ fees and costs, private attorneys are incentivized to bring CFA
    claims, thus reducing the enforcement burdens that otherwise would fall on the
    State, 
    Weinberg, 173 N.J. at 248-49
    .
    The CFA’s history “is one of constant expansion of consumer
    protection.” Gennari v. Weichert Co. Realtors, 
    148 N.J. 582
    , 604 (1997). The
    statute has been “repeatedly amended and expanded . . . often by adding
    sections to address particular areas of concern and to include them specifically
    within its protective sweep.” Czar, Inc. v. Heath, 
    198 N.J. 195
    , 201 (2009)
    (listing statutory changes).
    In addition to its ever-growing scope, “[t]he language of the CFA
    evinces a clear legislative intent that its provisions be applied broadly.”
    Lemelledo v. Beneficial Mgmt. Corp. of Am., 
    150 N.J. 255
    , 264 (1997).
    “[L]ike most remedial legislation, the [CFA] should be construed liberally in
    favor of consumers.” 
    Cox, 138 N.J. at 15
    .
    And, by the plain terms of the statute, “[t]he rights, remedies and
    prohibitions” created by the CFA are “in addition to and cumulative of any
    other right, remedy or prohibition accorded by the common law or statutes of
    this State.” N.J.S.A. 56:8-2.13. Courts are therefore reluctant “to undermine
    10
    the CFA’s enforcement structure . . . by carving out exemptions for each
    allegedly fraudulent practice that may concomitantly be regulated by another
    source of law.” 
    Lemelledo, 150 N.J. at 270
    .
    This Court considered the reach of the CFA in the context of other
    regulatory laws in Lemelledo v. Beneficial Management Corp. of America and
    Real v. Radir Wheels, Inc. We review those decisions in turn.
    1.
    In Lemelledo, a consumer brought a class action under the CFA against
    a financial services company for loan packing -- increasing a loan amount by
    including related services like credit insurance.
    Id. at 259-60.
    The defendant
    argued that the CFA was preempted by other statutes regulating consumer
    loans.
    Id. at 271-73.
    We rejected that argument, holding there is a
    “presumption that the CFA applies to a covered activity,” a presumption that
    can be overcome only when a court is satisfied “that a direct and unavoidable
    conflict exists between application of the CFA and application of the other
    regulatory scheme or schemes.”
    Id. at 270.
    Tying the claim in Lemelledo to the CFA’s purpose, we noted that,
    [i]f the hurdle for rebutting the basic assumption of
    applicability of the CFA to covered conduct is too
    easily overcome, the statute’s remedial measures may
    be rendered impotent as primary weapons in
    combatting clear forms of fraud simply because those
    11
    fraudulent practices happen also to be covered by some
    other statute or regulation.
    [Ibid.]
    With respect to other remedial statutes specifically, we noted that “[i]t is
    not readily to be inferred that the Legislature, by enacting multiple remedial
    statutes designed to augment protection, actually intended that parties be
    subject only to one source of regulation.”
    Id. at 271.
    We nevertheless held
    that, in applying statutes that cover the same conduct as the CFA, courts
    should avoid statutory interpretations that impose overlapping or conflicting
    duties and obligations:
    Conflicting applications of the respective statutes and
    regulatory schemes can be avoided if courts are
    cognizant of the obligations created by other statutes
    and if they interpret the scope of the broad language of
    the CFA so as not to impose conflicting duties or
    duplicative financial obligations on the regulated party.
    [Id. at 273.]
    2.
    Later, in Radir Wheels, we applied the principles set forth in Lemelledo
    in considering whether the Used Car Lemon Law, N.J.S.A. 56:8-67 to -80,
    preempted a CFA claim for fraudulent advertisement brought by the purchaser
    of a used automobile from a private seller. 
    198 N.J. 511
    , 514 (2009). The
    Appellate Division held that the consumer failed to state a cause of action
    12
    under the CFA because the “commercial activities of a casual seller . . . d[id]
    not fall within the CFA’s private civil cause of action.”
    Ibid. We disagreed. Discussing
    the standard for displacing the CFA set forth in Lemelledo,
    we noted that “[t]he measured application of those principles has led to few,
    very limited exceptions to the CFA’s reach.”
    Id. at 523
    (citing Macedo v.
    Dello Russo, 
    178 N.J. 340
    , 345-46 (2004) (explaining that the CFA does not
    apply to “learned professionals . . . operating in their professional capacities”);
    Daaleman v. Elizabethtown Gas Co., 
    77 N.J. 267
    , 272-73 (1978) (holding the
    CFA inapplicable “to public utility rates subject to the Board of Public
    Utilities’ exclusive rate-setting jurisdiction”)); see also
    id. at 523
    n.9
    (collecting examples of additional settings in which the CFA did not apply).
    Ultimately, we held that the consumer’s CFA claim was not preempted
    by the Used Car Lemon Law, which expressly provides that “[n]othing in this
    act shall in any way limit the rights or remedies which are otherwise available
    to a consumer under any other law.”
    Id. at 526
    (quoting N.J.S.A. 56:8-75).
    B.
    The PLA was enacted in 1987, nearly three decades after the CFA. See
    Dewey v. R.J. Reynolds Tobacco Co., 
    121 N.J. 69
    , 94-95 (1990). As a New
    Jersey tort-reform statute, the PLA codified certain issues relating to the
    13
    common law governing product liability actions and “establish[ed] new rules
    regarding the burden of proof and the imposition of liability.”
    Id. at 95.
    The PLA is intended to protect users from harm caused by defective
    products by “establish[ing] clear rules” in “actions for damages for harm
    caused by products.” N.J.S.A. 2A:58C-1(a). Specifically, the PLA imposes
    liability upon the manufacturer or seller for a product’s “manufacturing
    defects, warning defects, and design defects.” Assemb. Ins. Comm. Statement
    to S. Comm. Substitute for S. 2805 (L. 1987, c. 197) (June 22, 1987);
    Sponsor’s Statement to S. 2805 (L. 1987, c. 197) (Nov. 17, 1986); see also
    N.J.S.A. 2A:58C-2.
    Under the PLA, a claimant can recover damages against the
    “manufacturer or seller of a product” upon proof “that the product causing the
    harm was not reasonably fit, suitable or safe for its intended purpose.”
    N.J.S.A. 2A:58C-2. A “claimant” is “any person who brings a product liability
    action,” N.J.S.A. 2A:58C-1(b)(1), and a “product liability action” is a claim
    for harm caused by a manufacturing, warning, or design defect, “except
    actions for harm caused by breach of an express warranty,” N.J.S.A. 2A:58C-
    14
    1(b)(3).3 In addition to the exception for breach of an express warranty, the
    PLA excludes environmental tort actions. N.J.S.A. 2A:58C-6.
    Damages recoverable under the PLA for “harm” caused by the product
    are:
    (a) physical damage to property, other than to the
    product itself; (b) personal physical illness, injury or
    death; (c) pain and suffering, mental anguish or
    emotional harm; and (d) any loss of consortium or
    services or other loss deriving from any type of harm
    described in subparagraphs (a) through (c) of this
    paragraph.
    [N.J.S.A. 2A:58C-1(b)(2).]
    This Court has considered the kinds of claims covered by the PLA in In
    re Lead Paint Litigation and Sinclair v. Merck & Co. We review those cases
    below.
    1.
    Twenty years after enactment of the PLA, this Court decided Lead Paint
    in which we scrutinized a nuisance-based pleading and, based on a pleading-
    to-statute comparison, held that the PLA subsumed the plaintiffs’ common law
    public nuisance causes of action that were fundamentally PLA claims. 191
    3
    The PLA and its legislative history, to which the Legislature expressly
    encourages reference, makes clear that the PLA did not intend to wholly
    supplant the products liability case law in New Jersey. See N.J.S.A. 2A:58C-
    1(a). Thus, our focus must be on the PLA’s defined theories on which claims
    of harm may be actionable against a manufacturer or seller. See
    id. at -2. 15
    N.J. 405, 436-37 (2007). In Lead Paint, twenty-six municipalities and counties
    asserted common law public nuisance claims against manufacturers and
    distributors of lead paint, in part for the costs of medical care for lead
    poisoning and for the detection and removal of the paint.
    Id. at 408-09.
    In
    doing so, the municipalities sought to apply the environmental tort exception
    to the PLA, N.J.S.A. 2A:58C-6.
    Id. at 437.
    We found that the harms attributable to the lead paint -- physical damage
    to property and personal physical illness or injury -- were of the type intended
    to be remedied through the PLA. The common law claims asserted by the
    plaintiffs essentially sounded in “product liability” for failure to warn and
    were therefore also covered by the PLA.
    Id. at 436-40.
    The central focus of plaintiffs’ complaints is that
    defendants were aware of dangers associated with lead
    -- and by extension, with the dangers of including it in
    paint intended to be used in homes and businesses --
    and failed to warn of those dangers. This classic
    articulation of tort law duties, that is, to warn of or to
    make safe, is squarely within the theories included in
    the PLA.
    [
    Id. at 437.
    ]
    Thus, we determined that the theory of liability claimed by the plaintiffs was,
    in reality, a PLA claim and was therefore actionable only under the strictures
    of the PLA.
    Id. at 440.
    16
    2.
    One year later, in Sinclair, we considered whether plaintiffs who used
    the drug Vioxx could maintain both CFA and PLA claims. 
    195 N.J. 51
    , 54
    (2008). In that case, the plaintiffs sought certification of a nationwide class of
    individuals who took the drug “for at least six consecutive weeks” and “who
    had not sought to recover damages for personal injuries caused by Vioxx .”
    Id. at 55.
    The plaintiffs alleged that “as a result of their direct and prolonged
    consumption of Vioxx” they were at increased risk of future cardiac disorders
    like heart attack or stroke; they therefore sought medical monitoring and
    punitive damages.
    Id. at 55-56.
    Unlike the present case where Sun brought CFA and PLA claims in the
    same count of a single-count complaint, in Sinclair the CFA and PLA causes
    of action were brought in separate but nearly indistinguishable counts. First
    Amended Class Action Complaint for Damages and Equitable and Injunctive
    Relief ¶¶ 119, 123, Sinclair v. Merck & Co., ATL-L3771-04 MT (N.J. Super.
    Ct. Law Div. Mar. 17, 2015). Further, the relief the plaintiffs sought under the
    CFA count of the complaint matched the PLA count word-for-word. Compare
    id. ¶ 124
    with
    id. ¶ 133.
    The focus of Sinclair was whether the plaintiffs’ claimed risk of future
    cardiovascular injury was cognizable under the PLA despite their failure to
    17
    allege present physical injuries. We found that the plaintiffs’ claimed risk of
    future cardiovascular injury was not cognizable under the PLA because the
    statute “require[s] a physical injury.” 
    Sinclair, 195 N.J. at 64
    ; see
    ibid. (“Nothing in the
    legislative history of the PLA suggests that the Legislature
    intended to eliminate that physical component.”). More importantly, we
    determined, after considering the nature of the plaintiffs’ allegations, that the
    plaintiffs sought “to avoid the requirements of the PLA by asserting their
    claims as CFA claims,” even though “[t]he heart of [their] case [was] the
    potential for harm caused by Merck’s drug.”
    Id. at 65-66.
    That claim, we
    explained, “does not fall within an exception to the PLA, but rather clearly
    falls within its scope.”
    Id. at 66. IV.
    A.
    As our review of the statutes reveals, the CFA and PLA are intended to
    govern different conduct and to provide different remedies for such conduct.
    There is thus no direct and unavoidable conflict between the CFA and PLA.
    The PLA governs the legal universe of products liability actions as defined in
    that Act and the CFA applies to fraud and misrepresentation and provides
    unique remedies intended to root out such conduct.
    18
    We have stressed that the PLA cannot be stretched to encompass claims
    sounding in contract, noting that the PLA’s definition of harm “draw[s] a clear
    line between remedies available in tort and contract.” See Dean v. Barrett
    Homes, Inc., 
    204 N.J. 286
    , 305 (2010). Although we have thus rejected the
    idea that contract-based claims could be pled under the PLA, we have not yet
    considered the question at the center of this matter: whether tort-based claims
    that can be pled under the PLA can also -- or instead -- be pled under the CFA.
    Legislative intent to allow certain CFA claims to co-exist with separately
    pled statutory PLA claims may be found in the CFA’s 1990 and 2007
    amendments requiring notice and prohibiting the sale of certain defective,
    hazardous, or dangerous children’s products. See N.J.S.A. 56:8-20, -51,
    and -53.1 to -53.5. Those post-PLA amendments to the CFA evidence the
    statutes’ complementary nature since both concern product safety and the
    protection of child consumers. Violation of either amendment would give rise
    to a CFA claim irrespective of whether a product defect caused injury
    actionable under the PLA. The failure to warn of a product defect is likewise
    cognizable under the PLA, N.J.S.A. 2A:58C-2 (identifying as actionable the
    failure to provide adequate warnings or instructions for a product), while an
    affirmative misrepresentation that a specific flaw did not exist or a product had
    never failed may be brought under the CFA, N.J.S.A. 56:8-2 (identifying as
    19
    actionable a “misrepresentation or the knowing[] concealment, suppression or
    omission of any material fact”).
    If a claim is premised upon a product’s manufacturing, warning, or
    design defect, that claim must be brought under the PLA with damages limited
    to those available under that statute; CFA claims for the same conduct are
    precluded. But nothing about the PLA prohibits a claimant from seeking relief
    under the CFA for deceptive, fraudulent, misleading, and other unconscionable
    commercial practices in the sale of the product. Indeed, the CFA is expressly
    “in addition to and cumulative of any other right, remedy or prohibition
    accorded by the common law or statutes of this State.” N.J.S.A. 56:8-2.13.
    Said differently, if a claim is based on deceptive, fraudulent, misleading, and
    other unconscionable commercial practices, it is not covered by the PLA and
    may be brought as a separate CFA claim.
    We agree with amici that PLA and CFA claims may proceed in separate
    counts of the same suit, alleging different theories of liability and seeking
    dissimilar damages. As we noted in Lemelledo, CFA rights and remedies are
    “cumulative to those created by other sources of 
    law,” 150 N.J. at 264
    , 268,
    and the presumptive application of the CFA is overcome only if “a direct and
    unavoidable conflict exists between application of the CFA and application of
    the other regulatory scheme or schemes,”
    id. at 270. 20
          And as we pointed out in Sinclair, had the Legislature intended for the
    PLA to preempt, displace, or subsume the CFA, it would have said 
    so. 195 N.J. at 65-66
    ; see also DiProspero v. Penn, 
    183 N.J. 477
    , 494-95 (2005)
    (“[T]he Legislature knows how to incorporate into a new statute a standard
    articulated in a prior opinion of this Court.”); Miah v. Ahmed, 
    179 N.J. 511
    ,
    520 (2004) (explaining that judicial interpretation begins with the plain
    language of the statute). Instead, as noted above, the Legislature has
    announced the opposite -- the CFA supplements any other right or remedy
    available. See N.J.S.A. 56:8-2.13.
    Neither the Federal Rules of Civil Procedure nor the New Jersey Court
    Rules preclude separate claims premised upon separate theories of liability
    from being advanced in the same pleading and sought at the same trial. See
    Fed. R. Civ. P. 8(d)(3) (“A party may state as many separate claims or
    defenses as it has, regardless of consistency.”); R. 4:5-6 (“As many separate
    claims or defenses as the party has may be stated regardless of their
    consistency and whether based on legal or on equitable grounds or on both.”).
    B.
    How a given claim must be pled, in turn, depends on what is at the
    “heart of plaintiffs’ case” -- the underlying theory of liability. 
    Sinclair, 195 N.J. at 66
    .
    21
    The phrase “the essential nature of the claim[]” was referenced by this
    Court in Lead Paint when we were engaged in a review of the pleadings to
    determine whether the theory pled on the facts presented, although denoted as
    a nuisance claim, was in fact one of the three codified theories made
    exclusively actionable under the 
    PLA. 191 N.J. at 437
    . If so, then the claim
    was supplanted by the PLA. Although helpful in explaining our analysis in
    that matter, it is not to be regarded as the interpretative guide to the PLA. It is
    best understood not as an assessment of whether a claim is for harm caused by
    a product, but of whether the claim is based upon a product’s manufacturing,
    warning, or design defect and therefore covered by the PLA. See 
    Sinclair, 195 N.J. at 54
    , 62 (finding the “essential nature” of the disputed pleading to be a
    product defect claim); Lead 
    Paint, 191 N.J. at 437
    (finding the disputed
    pleading to be essentially a failure to warn claim).
    We noted in Sinclair that the Legislature intended that the defined
    products liability actions remain “within the scope of the 
    PLA,” 195 N.J. at 65
    ,
    and expressly excluded from that “actions for harm caused by breach of an
    express warranty,”
    id. at 62
    (quoting N.J.S.A. 2A:58C-1(b)(3)). Notably,
    breach of an express warranty may be covered by the CFA as a misleading
    commercial practice. See N.J.S.A. 56:8-2 (declaring unlawful the use of a
    “false promise . . . in connection with the sale or advertisement of any
    22
    merchandise”). Thus, aside from breach of express warranty claims, 4 claims
    that sound in the type of products liability actions defined in the PLA must be
    brought under the PLA.
    Significantly, it is the nature of the action giving rise to a claim that
    determines how a claim is characterized. Sun is mistaken in its heavy reliance
    on the nature of the damages it seeks, claiming they are economic losses rather
    than damages for injury to persons or property. The nature of the plaintiff’s
    damages does not determine whether the cause of action falls under the CFA
    or PLA; rather, it is the theory of liability underlying the claim that determines
    the recoverable damages.
    Therefore, a CFA claim alleging express misrepresentations -- deceptive,
    fraudulent, misleading, and other unconscionable commercial practices -- may
    be brought in the same action as a PLA claim premised upon product
    manufacturing, warning, or design defects. In other words, the PLA will not
    bar a CFA claim alleging express or affirmative misrepresentations.
    V.
    For the reasons set forth above, we answer the certified question in the
    affirmative. A CFA claim alleging express or affirmative misrepresentations
    4
    As explained previously, environmental tort actions are also excepted from
    the PLA. N.J.S.A. 2A:58C-6.
    23
    -- deceptive, fraudulent, misleading, and other unconscionable commercial
    practices -- may proceed in separate counts of the same pleading as a PLA
    claim alleging product design, manufacturing, or warning defects.
    CHIEF JUSTICE RABNER and JUSTICES LaVECCHIA, ALBIN, and
    FERNANDEZ-VINA join in JUSTICE SOLOMON’s opinion. JUSTICES
    PATTERSON and TIMPONE did not participate.
    24